Athira pharma announces formation of scientific advisory board comprised of renowned leaders in neurology research

Bothell, wash., june 07, 2022 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a scientific advisory board (sab) comprised of renowned leaders in neurology and neurodegenerative disease research – drs. john olichney, anton porsteinsson, marwan sabbagh, lon schneider, pierre tairot and paul winner. the sab, chaired by athira chief medical officer, dr. hans moebius, will offer expert scientific and clinical perspectives to guide the ongoing development of athira's pipeline of novel, small molecule compounds.
ATHA Ratings Summary
ATHA Quant Ranking